A Marcos-Delgado1, E López-García2, M A Martínez-González3, J Salas-Salvadó4, D Corella5, M Fitó6, D Romaguera7, J Vioque8, A M Alonso-Gómez9, J Wärnberg10, J A Martínez11, L Serra-Majem12, R Estruch13, J C Fernández-García14, J Lapetra15, X Pintó16, J A Tur17, J López-Miranda18, N Cano-Ibañez19, M Delgado-Rodríguez20, P Matía-Martín21, L Daimiel22, E Carriedo23, J Vidal24, C Vázquez25, E Ros26, E Lozano-Oloriz27, M Bulló28, J V Sorlí5, M D Zomeño29, M Fiol7, S González-Palacios8, C Sorto-Sánchez30, N Pérez-Farinós31, N Goñi-Ruiz27, A Sanchez-Villegas12, A Muñoz-Garach32, J M Santos-Lozano33, A Galera34, C Bouzas17, E Toledo35, N Babio28, J I González5, J L Del Val-García36, M Moñino7, M C Martínez-Vergaran8, L Goicolea-Güemez9, I Galilea-Zabalza37, J Basora38, M A Muñoz39, P Builf27, T Fernández-Villa40. 1. The Research Group in Gene - Environment and Health Interactions, IBIOMED - University of León, León, Spain; Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, University of León, León, Spain. 2. Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU; Vitoria-Gasteiz, Spain; Nutritional Genomics and Epigenomics Group, IMDEA Food Institute, CEI UAM+CSIC, Madrid, Spain; Department of Preventive Medicine and Public Health, Universidad Autónoma de Madrid/ IdiPaz, Madrid, Spain. 3. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 4. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Reus, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain. 5. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain. 6. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), Barcelona, Spain. 7. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. 8. CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Miguel Hernandez University, ISABIAL-FISABIO, Alicante, Spain. 9. Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU; Vitoria-Gasteiz, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. 10. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Nursing, School of Health Sciences, University of Málaga-Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain. 11. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain; Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. 12. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Nutrition Research Group, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. 13. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. 14. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Virgen de la Victoria Hospital, Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain. 15. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain. 16. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; University of Barcelona, Spain. 17. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain. 18. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. 19. CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. 20. Department of Nursing, School of Health Sciences, University of Málaga-Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain; Division of Preventive Medicine, Faculty of Medicine, University of Jaén, Jaén, Spain. 21. Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 22. Nutritional Genomics and Epigenomics Group, IMDEA Food Institute, CEI UAM+CSIC, Madrid, Spain. 23. Centro de Salud de José Aguado. Gerencia de Atención Primaria de León. 24. Department of Endocrinology, Institut d'Investigacions Biomédiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain; CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 25. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain. 26. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain. 27. University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain. 28. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain. 29. Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), Barcelona, Spain; Blanquerna, School of Health Sciences, Universitat Ramon Llull, Barcelona. 30. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU; Vitoria-Gasteiz, Spain. 31. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Departament of Public Health, University of Málaga-Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain. 32. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Virgen de la Victoria Hospital, Department of Endocrinology, Instituto de Investigación Biomédica de Málaga (IBIMA). University of Málaga, Málaga, Spain; Hospital Virgen de las Nieves de Granada, Departament of Endocrinology and Nutrition. 33. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Departament of Medicine, University of Sevilla, Sevilla, Spain. 34. Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. 35. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, Pamplona, Spain. 36. Institut Català de la Salut and IDIAP Jordi Gol, Barcelona, Spain. 37. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. 38. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Reus, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; Institut Català de la Salut and IDIAP Jordi Gol, Barcelona, Spain. 39. Unitat de Suport a la Recerca de Barcelona. IDIAPJGol. Gerencia de Atención Primaria de Barcelona. Institut Català de la Salut, Barcelona. 40. The Research Group in Gene - Environment and Health Interactions, IBIOMED - University of León, León, Spain; Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, University of León, León, Spain. Electronic address: tferv@unileon.es.
Abstract
INTRODUCTION AND OBJECTIVES: Metabolic syndrome (MetS) is a combination of various cardiovascular risk factors with a major impact on morbidity and premature mortality. However, the impact of MetS on self-reported health-related quality of life (HRQoL) is unknown. This study evaluated the HRQoL in a Spanish adult population aged 55 years and older with MetS. METHOD: A cross-sectional analysis was performed with baseline data from the PREDIMED-Plus multicentre randomized trial. The participants were 6430 men and women aged 55-75 years with overweight/obesity (body mass index ≥27 and ≤40kg/m2) and MetS. The SF-36 questionnaire was used as a tool to measure HRQoL. Scores were calculated on each scale of the SF-36 by gender and age. RESULTS: Participants showed higher scores in the social function (mean 85.9, 95% CI; 85.4-86.4) and emotional role scales (mean 86.8, 95% CI; 86.0-87.5). By contrast, the worst scores were obtained in the aggregated physical dimensions. In addition, men obtained higher scores than women on all scales. Among men, the worst score was obtained in general health (mean 65.6, 95% CI; 65.0-66.2), and among women, in body pain (mean 54.3, 95%CI; 53.4-55.2). A significant decrease was found in the aggregated physical dimensions score among participants 70-75 years old, but an increased one in the aggregated mental dimensions, compared to younger participants. CONCLUSIONS: Our results reflect that the MetS may negatively affect HRQoL in the aggregated physical dimensions, body pain in women, and general health in men. However, this adverse association was absent for the psychological dimensions of HRQoL, which were less affected.
RCT Entities:
INTRODUCTION AND OBJECTIVES:Metabolic syndrome (MetS) is a combination of various cardiovascular risk factors with a major impact on morbidity and premature mortality. However, the impact of MetS on self-reported health-related quality of life (HRQoL) is unknown. This study evaluated the HRQoL in a Spanish adult population aged 55 years and older with MetS. METHOD: A cross-sectional analysis was performed with baseline data from the PREDIMED-Plus multicentre randomized trial. The participants were 6430 men and women aged 55-75 years with overweight/obesity (body mass index ≥27 and ≤40kg/m2) and MetS. The SF-36 questionnaire was used as a tool to measure HRQoL. Scores were calculated on each scale of the SF-36 by gender and age. RESULTS:Participants showed higher scores in the social function (mean 85.9, 95% CI; 85.4-86.4) and emotional role scales (mean 86.8, 95% CI; 86.0-87.5). By contrast, the worst scores were obtained in the aggregated physical dimensions. In addition, men obtained higher scores than women on all scales. Among men, the worst score was obtained in general health (mean 65.6, 95% CI; 65.0-66.2), and among women, in body pain (mean 54.3, 95%CI; 53.4-55.2). A significant decrease was found in the aggregated physical dimensions score among participants 70-75 years old, but an increased one in the aggregated mental dimensions, compared to younger participants. CONCLUSIONS: Our results reflect that the MetS may negatively affect HRQoL in the aggregated physical dimensions, body pain in women, and general health in men. However, this adverse association was absent for the psychological dimensions of HRQoL, which were less affected.
Keywords:
Bienestar; Calidad de vida relacionada con la salud; Health-Related Quality of Life; Metabolic Syndrome; Obesidad; Obesity; PREDIMED-Plus; Pérdida de peso; Weight-loss; Well-being.
Authors: Alba Marcos-Delgado; Natalia Hernández-Segura; Tania Fernández-Villa; Antonio J Molina; Vicente Martín Journal: Int J Environ Res Public Health Date: 2021-01-20 Impact factor: 3.390
Authors: Cristina Bouzas; Maria Del Mar Bibiloni; Silvia Garcia; David Mateos; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Albert Goday; J Alfredo Martínez; Ángel M Alonso-Gómez; Julia Wärnberg; Jesús Vioque; Dora Romaguera; José Lopez-Miranda; Ramon Estruch; Francisco J Tinahones; José Lapetra; Lluís Serra-Majem; Blanca Riquelme-Gallego; Vicente Martín-Sánchez; Xavier Pintó; José J Gaforio; Pilar Matía; Josep Vidal; Clotilde Vázquez; Lidia Daimiel; Emilio Ros; Elena Pascual-Roquet-Jalmar; Nancy Babio; Inmaculada Gonzalez-Monge; Olga Castañer; Itziar Abete; Carolina Sorto-Sánchez; Juan Carlos Benavente-Marín; Laura Torres-Collado; Marian Martin; Antonio García-Ríos; Sara Castro-Barquero; Jose C Fernández-García; José Manuel Santos-Lozano; Cesar I Fernandez-Lazaro; Albert Salas-Huetos; Patricia Guillem-Saiz; María Dolores Zomeño; Maria Ángeles Zulet; Amaia Goikoetxea-Bahon; Alfredo Gea; Stephanie K Nishi; Helmut Schröder; Josep A Tur Journal: Front Nutr Date: 2022-07-22
Authors: Michael Jeitler; Romy Lauche; Christoph Hohmann; Kyung-Eun Anna Choi; Nadia Schneider; Nico Steckhan; Florian Rathjens; Dennis Anheyer; Anna Paul; Christel von Scheidt; Thomas Ostermann; Elisabeth Schneider; Daniela Koppold-Liebscher; Christian S Kessler; Gustav Dobos; Andreas Michalsen; Holger Cramer Journal: Nutrients Date: 2022-08-29 Impact factor: 6.706